Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
Acacia Pharma has now established its initial US sales and marketing infrastructure, ahead of the potential launch of lead asset BARHEMSYS. This is the first step in its strategy to bring antiemetic drugs to the hospital setting for unmet needs in PONV and CINV. The FDA has accepted Acacia’s revised New Drug Application (NDA) for BARHEMSYS and has now set a Prescription Drug User Fee Act (PDUFA) date of 5 May. We continue to expect launch of BARHEMSYS in H119. We value Acacia at €635m (or €11.9/share) vs €602m (or €11.3/share) previously.
Written by
Acacia Pharma |
Ready for BARHEMSYS launch in H119 |
FY18 results |
Pharma & biotech |
27 February 2019 |
Share price performance
Business description
Next events
Analysts
Acacia Pharma is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Acacia Pharma has now established its initial US sales and marketing infrastructure, ahead of the potential launch of lead asset BARHEMSYS. This is the first step in its strategy to bring antiemetic drugs to the hospital setting for unmet needs in PONV and CINV. The FDA has accepted Acacia’s revised New Drug Application (NDA) for BARHEMSYS and has now set a Prescription Drug User Fee Act (PDUFA) date of 5 May. We continue to expect launch of BARHEMSYS in H119. We value Acacia at €635m (or €11.9/share) vs €602m (or €11.3/share) previously.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
0.0 |
(6.5) |
(2.32) |
0.00 |
N/A |
N/A |
12/18 |
0.0 |
(16.2) |
(0.35) |
0.00 |
N/A |
N/A |
12/19e |
1.1 |
(46.0) |
(0.83) |
0.00 |
N/A |
N/A |
12/20e |
13.5 |
(41.7) |
(0.76) |
0.00 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
CRL deficiencies addressed and PDUFA date set
Following the submission of the original NDA for BARHEMSYS, the FDA issued a complete response letter (CRL) that related to issues at the contract manufacturer responsible for producing the active pharmaceutical ingredient (API). Acacia and the API manufacturer prepared a corrective and preventative action plan to address the outstanding deficiencies at the manufacturing facility. This plan was submitted to the FDA by the contract manufacturer alongside a resubmission of the NDA by Acacia. Importantly, the FDA did not request additional clinical data. We do not anticipate any additional problems and expect BARHEMSYS to be approved on or before its PDUFA date. However, sensitivities remain until approval is achieved.
US commercial infrastructure in place
Acacia has hired 35 staff in the US (in sales, regulatory, marketing and operational roles) in preparation for a launch of BARHEMSYS in H119. By mid-2019 Acacia expects this to rise to 40 staff as the drug nears approval and to 100 once direct field staff have been employed. Reps will focus on anaesthetists at ~1,600 US hospitals that account for ~80% of relevant surgical procedures. We estimate that successful commercialisation could enable Acacia to achieve break-even in 2023.
FY18 results: Building US operations
Net loss rose to £15.5m in FY18 vs £6.2m in FY17, predominately as a result of increased SG&A (FY18: £11.3m vs FY17: £1.5m) expenses as Acacia prepares for the US launch of BARHEMSYS. We forecast this trend to continue with a net loss of £44.4m in FY19 driven by significant investment in sales and marketing. Near-term funding will be required to grow the US operations (see our initiation report).
Valuation: €635m or €11.9/share
Our valuation has increased to €635m or €11.9/share vs €602m or €11.3/share previously. This is a result of updating for net cash, FX rates and rolling forward our model. Our valuation is predominantly based on a risk-adjusted NPV model of BARHEMSYS for PONV, in addition to the CINV opportunity for the US market only.
R&D activities strengthen company
Acacia continues to advance its R&D operations, as noted in recent publications and announcements on BARHEMSYS. In November 2018, Acacia published its data from the positive Phase III clinical trial of BARHEMSYS as rescue treatment for established PONV (post-operative nausea and vomiting) in the journal Anesthesiology. In January 2019, the company announced positive cardiac data (DP10022 study) for BARHEMSYS, which demonstrated that there was no significant risk of heart rhythm disturbances (arrhythmias) at the highest proposed dose of BARHEMSYS, given alone or in combination with intravenous ondansetron, a widely used PONV therapy with a known effect on the heart.
As a result of its strong clinical data package to date, the company is seeking the following label from the FDA:
1.
treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or who have not received prophylaxis (at a dose of 10mg); and
2.
prevention of PONV, either alone or in combination with an antiemetic of a different class (at a dose of 5mg).
In addition to BARHEMSYS, Acacia is developing APD403 (repurposed amisulpride, the active ingredient in BARHEMSYS, in both an intravenous form for use alongside chemotherapy and an oral version for use at home in the subsequent days) for management of chemotherapy-induced nausea and vomiting (CINV) as a follow-on indication. In December 2018, the company announced its positive Phase II clinical trial data of APD403 in CINV had been published in the journal Supportive Care in Cancer.
FY18 results: Cost base rises as it readies for launch
Acacia continues to ramp up its US commercial operations in preparation for launch of BARHEMSYS (amisulpride injection). As result, SG&A increased in FY18 to £11.3m vs £1.5m in FY17. The increase was predominately driven by sales and marketing costs of £6.9m (vs FY17: £0.0) from hiring a new commercial team and the subsequent pre-launch marketing, education, training, distribution and regulatory activities. G&A costs rose to £4.3m in FY18 (vs FY17: £1.5m) as a result of the costs of the Euronext IPO and ongoing costs of being a public company. R&D rose to £3.8m (vs FY17: £1.5m) as a result of the NDA submission, product development and the DP10022 study.
Financial income rose to £0.9m (vs FY17: £0.002m) due to the increased cash balance from the IPO, while financial expenses dropped to £2.1m (vs FY17: £3.5m) because of the conversion of both the preferred shares and the convertible loan. Tax credits rose slightly to £0.7m (vs FY17: £0.3m).
Net loss rose in FY18 to £15.5m (vs FY17: £6.2m). The year-end cash balance of £29.4m was aided by the £33.9m net raise from the IPO in March and the drawdown of $10m from the $30m credit facility with Hercules Technology Growth Capital (Hercules). In FY18, the company repaid the existing £5.2m Silicon Valley Bank loan. To fund ongoing operations, we forecast that an additional c £70m (in addition to the remaining $20m from Hercules) will need to be raised in 2019 and 2020. We note that, for simplicity, in our model we currently illustrate this as a debt raise. However, Acacia management has stated that it plans to finance the company by a combination of equity and debt.
We forecast revenue in FY19 of £1.1m, growing to £13.5m in FY20. In the short term, revenues remain wholly dependent on the success of BARHEMSYS. We project R&D costs of £7.6m in FY19, growing to £9.9m in FY20, driven by the clinical trial programme for APD403. We anticipate that SG&A costs will increase to £37.1m in FY19, growing to £42.0m in FY20. We forecast a net loss of £44.4m in FY19 and £40.4m in FY20, and that Acacia will reach break-even in 2023.
Research: Metals & Mining
On 26 February, Amur announced the long-awaited results of its updated pre-feasibility study (PFS) into its Kun-Manie project in Russia’s Far East. In contrast to previous studies, the PFS considered just two options, namely a toll smelt option and a low-grade matte option, and dispensed with the high-grade matte and refinery options. Detailed financial models are not yet available. However, both considered a 6Mtpa mining operation and results are comparable to those published by Edison in our note, Cobalt-plated nickel, published on 16 April 2018.